Prognostic and therapeutic implications of increased ATP citrate lyase expression in human epithelial ovarian cancer

Wang,Yu; Wang,Yunxia; Shen,Liang; Pang,Yingxin; Qiao,Zhen; Liu,Peishu

doi:10.3892/or.2012.1638

Prognostic and therapeutic implications of increased ATP citrate lyase expression in human epithelial ovarian cancer

Authors:
- Yu Wang
- Yunxia Wang
- Liang Shen
- Yingxin Pang
- Zhen Qiao
- Peishu Liu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China, Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, No 107 Wen Hua Xi Road, Jinan, Shandong 250012, P.R. China
Published online on: January 16, 2012 https://doi.org/10.3892/or.2012.1638
Pages: 1156-1162

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Altered metabolism is one of the most significant features of cancer cells. ATP citrate lyase (ACL), a key enzyme in de novo lipid synthesis, has been reported to be overexpressed or activated in several cancer types. To determine the role of ACL in ovarian cancer progression, we detected ACL expression in human epithelial ovarian cancer tissues. qRT-PCR and western blotting showed higher ACL expression in malignant tissues compared to normal ovarian tissues. Immunohistochemical analysis showed that phosphorylated ACL was increased in ovarian cancer tissues and that its expression correlated well with tumor grade, FIGO stage and poorer prognosis. To explore the therapeutic potential of ACL, we assessed the effect of ACL-siRNA on cellular proliferation and cell cycle distribution. ACL knockdown inhibited cellular proliferation and induced cell cycle arrest in A2780 cells. Taken together, our findings suggest that ACL may contribute to the pathogenesis of human epithelial ovarian cancer, and may serve as a novel therapeutic target.

View Figures

View References

1	Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
2	Mashima T, Seimiya H and Tsuruo T: De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer. 100:1369–1372. 2009. View Article : Google Scholar : PubMed/NCBI
3	Furuta E, Okuda H, Kobayashi A and Watabe K: Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta. 1805:141–152. 2010.PubMed/NCBI
4	Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR and Thompson CB: ATP-citrate lyase links cellular metabolism to histone acetylation. Science. 324:1076–1080. 2009. View Article : Google Scholar : PubMed/NCBI
5	Hatzivassiliou G, Zhao F, Bauer DE, et al: ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 8:311–321. 2005. View Article : Google Scholar : PubMed/NCBI
6	Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C and Thompson CB: ATP citrate lyase is an important component of cell growth and transformation. Oncogene. 24:6314–6322. 2005. View Article : Google Scholar : PubMed/NCBI
7	Migita T, Narita T, Nomura K, et al: ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res. 68:8547–8554. 2008. View Article : Google Scholar : PubMed/NCBI
8	Beckner ME, Fellows-Mayle W, Zhang Z, et al: Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas. Int J Cancer. 126:2282–2295. 2010.PubMed/NCBI
9	Zhou W, Han WF, Landree LE, et al: Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res. 67:2964–2971. 2007. View Article : Google Scholar : PubMed/NCBI
10	Iorio E, Mezzanzanica D, Alberti P, et al: Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 65:9369–9376. 2005. View Article : Google Scholar : PubMed/NCBI
11	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
12	Kuhajda FP: Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition. 16:202–208. 2000. View Article : Google Scholar : PubMed/NCBI
13	Ookhtens M, Kannan R, Lyon I and Baker N: Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am J Physiol. 247:R146–R153. 1984.PubMed/NCBI
14	Swinnen JV, Brusselmans K and Verhoeven G: Increassed lipogenesis in cancer cells: new players, novel target. Curr Opin Clin Nutr Metab Care. 9:358–365. 2006. View Article : Google Scholar : PubMed/NCBI
15	Pelicano H, Martin DS, Xu RH and Huang P: Glycolysis inhibition for anticancer treatment. Oncogene. 25:4633–4646. 2006. View Article : Google Scholar : PubMed/NCBI
16	Luo J, Manning BD and Cantley LC: Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI
17	Mazzoletti M and Broggini M: PI3K/AKT/mTOR inhibitors in ovarian cancer. Curr Med Chem. 17:4433–4447. 2010. View Article : Google Scholar : PubMed/NCBI
18	Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and Gonzalez-Baron M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 30:193–204. 2004.PubMed/NCBI
19	Bababeygy SR, Polevaya NV, Youssef S, et al: HMG-CoA reductase inhibition causes increased necrosis and apoptosis in an in vivo mouse glioblastoma multiforme model. Anticancer Res. 29:4901–4908. 2009.PubMed/NCBI
20	Relja B, Meder F, Wilhelm K, Henrich D, Marzi I and Lehnert M: Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 26:735–741. 2010. View Article : Google Scholar : PubMed/NCBI
21	Walter K, Hong SM, Nyhan S, et al: Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidemiol Biomarkers Prev. 18:2380–2385. 2009. View Article : Google Scholar : PubMed/NCBI
22	Migita T, Ruiz S, Fornari A, et al: Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 101:519–532. 2009. View Article : Google Scholar : PubMed/NCBI
23	Hilvo M, Denkert C, Lehtinen L, et al: Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res. 71:3236–3245. 2011. View Article : Google Scholar
24	Wang C, Xu C, Sun M, Luo D, Liao DF and Cao D: Acetyl-CoA carboxylase-alpha inhibitor TOFA induces human cancer cell apoptosis. Biochem Biophys Res Commun. 385:302–306. 2009. View Article : Google Scholar : PubMed/NCBI
25	Turyn J, Schlichtholz B, Dettlaff-Pokora A, et al: Increased activity of glycerol 3-phosphate dehydrogenase and other lipogenic enzymes in human bladder cancer. Horm Metab Res. 35:565–569. 2003. View Article : Google Scholar : PubMed/NCBI
26	Szutowicz A, Kwiatkowski J and Angielski S: Lipogenetic and glycolytic enzyme activities in carcinoma and nonmalignant diseases of the human breast. Br J Cancer. 39:681–687. 1979. View Article : Google Scholar : PubMed/NCBI
27	Yahagi N, Shimano H, Hasegawa K, et al: Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer. 41:1316–1322. 2005. View Article : Google Scholar : PubMed/NCBI
28	Varis A, Wolf M, Monni O, et al: Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res. 62:2625–2629. 2002.PubMed/NCBI
29	Moon YA, Lee JJ, Park SW, Ahn YH and Kim KS: The roles of sterol regulatory element-binding proteins in the transactivation of the rat ATP citrate-lyase promoter. J Biol Chem. 275:30280–30286. 2000. View Article : Google Scholar : PubMed/NCBI
30	Sato R, Okamoto A, Inoue J, et al: Transcriptional regulation of the ATP citrate-lyase gene by sterol regulatory element-binding proteins. J Biol Chem. 275:12497–12502. 2000. View Article : Google Scholar : PubMed/NCBI